Article: Manage skin toxicities associated with targeted therapies.(AS SEEN IN THE CLINICAL JOURNAL OF ONCOLOGY NURSING)

Article: What kind of rash is it? Deciphering the dermatologic ...
Clinical Journal of Oncology Nursing;  October 1, 2007 ;     700+ words ... ... literature related to dermatologic toxicities observed with many newer ... receptor--and associated dermatologic toxicities. Skin toxicities are not new phenomena ... describe the various skin toxicities that can occur with ...

Article: Manage skin toxicities associated with EGFR ...
ONS Connect;  June 1, 2008 ;     700+ words ... ... 2006 to discuss EGFR inhibitor-associated skin toxicities. Skin toxicities are a common side effect of EGFR inhibitors ... treatment options for EGFR inhibitor-associated skin toxicities have been published; therefore, no peer ...

Article: New Data Show Preemptive Treatment May Significantly Reduce ...
Business Wire;  June 26, 2008 ;     700+ words ... ... preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer ... incidence rate of grade 2 and greater skin toxicities by over 50 percent without additional ... The incidence of grade 3 or greater skin toxicities were 62 percent and 29 percent in ...

Article: Nevirapine (VIRAMUNE [R]) Strengthens Warning on Liver, ...
AIDS Treatment News;  November 17, 2000 ;     700+ words ...On November 9 Boehringer Ingelheim Roxane Laboratories notified medical professionals that the FDA-required labeling for its drug nevirapine had strengthened its warnings about risks of liver and other toxicities, due to reported cases of serious or fatal reactions to the drug. All future U.S.

Article: Review of panitumumab: a targeted therapy.(Oncology Nursing 101)
Clinical Journal of Oncology Nursing;  February 1, 2008 ;     700+ words ... ... side effects, including skin toxicities and diarrhea (Gaguski ... cetuximab side effects include dermatologic toxicities, interstitial lung disease ... manageable side effects of skin toxicities, hypomagnesemia, and diarrhea ...

Article: Amgen Releases Updated Results from 'STEPP' Trial.(Clinical ...
Health & Beauty Close-Up;  June 29, 2008 ;     700+ words ... ... preemptive and reactive skin treatment for skin toxicities in metastatic colorectal cancer ... incidence rate of grade 2 and greater skin toxicities by over 50 percent without additional ... The incidence of grade 3 or greater skin toxicities were 62 percent and 29 percent in ...

Article: Amgen to Appeal CHMP Opinion on Vectibix(TM) (Panitumumab).
Business Wire;  May 25, 2007 ;     700+ words ... ... Important Product Safety Information Dermatologic toxicities, related to Vectibix blockade ... dry skin, and skin fissures. Dermatologic toxicities were reported in 89 percent of ... 12 percent of patients. Severe dermatologic toxicities were complicated by infection ...